EpiVacCorona vaccine effective against all coronavirus strains - developer
MOSCOW. April 28 (Interfax) - The EpiVacCorona coronavirus vaccine is effective against all strains of Covid-19, deputy head of Rospotrebnadzor s Vector Center Tatyana Nepomnyashchikh said. At present, the vaccine is effective against the strains that are circulating, Nepomnyashchikh said at the Molecular Diagnostics and Security 2021 online congress on Wednesday. An important question arises now as to how much the composition of the vaccine will have to be changed due to the changing strains, whether the vaccine is effective. We are constantly monitoring, analyzing, looking in what areas (of the S protein of coronavirus) mutation occurs. And no mutations have currently been found in the area of the peptides used by us, she said.
New COVID-19 testing strategy can quicken test results for healthcare workers
Fast turnaround of COVID-19 test results for healthcare workers is critical. Investigators have now developed a COVID-19 testing strategy that maximizes the proportion of negative results after a single round of testing, allowing prompt notification of results. The method also reduces the need for increasingly limited test reagents, as fewer additional tests are required. Their strategy is described in the
Journal of Molecular Diagnostics, published by Elsevier.
There is an urgent need to reduce the spread of COVID-19 transmission in hospitals and care facilities and to maintain adequate levels of staffing. Group testing strategies with pooled samples have been proposed to increase capacity; however, the currently used strategies are slow.
Northwestern spinoff company Minute Molecular Diagnostics was awarded a $21.3 million grant from National Institutes of Health to produce pilot cartridges for a COVID-19 test that takes a single swab, according to a Monday University news release.
The technology, called Diagnostic Analyzer for Specific Hybridization, was developed at the Center for Innovation in Global Health Technologies, where McCormick Prof. David Kelso and Director of Research Sally McFall co-led device development.
In addition to its easy application, DASH makes positive or negative test results available in 15 minutes. Users can perform a nasal swab, enclose the swab in a cartridge and insert it into a testing unit.
Share this article
Share this article
ZARAGOZA, Spain and FRANKLIN LAKES, N.J., April 27, 2021 /PRNewswire/ CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit for the BD MAX™ Molecular Diagnostic System can now be run on saliva specimens.
This allows BD MAX™ System users more flexibility with three alternatives for specimen collection: nasopharyngeal, oropharyngeal and saliva. This kit, CE marked to the IVD Directive (98/79/CE), detects all currently identified variants of SARS-CoV-2.
CerTest Biotec and BD announced the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit for the BD MAX™ Molecular Diagnostic System can now be run on saliva specimens.
BD, CerTest Biotec Say Their Real-time PCR Detection Kit Can Now Run On Saliva Specimens
BD MAX System users now have three alternatives for specimen collection including nasopharyngeal, oropharyngeal and saliva.
This CE marked kit detects all currently identified variants of SARS-CoV-2, the companies said. This new specimen type alternative for VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for the BD MAXT System is complementing our versatile respiratory menu and is one step further in our goal to reach more patients with the right test and at the right time, said Nikos Pavlidis, vice president of Molecular Diagnostics at BD.